SI1000048T1 - Substituirani 1,2,3,4-tetrahidronaftalenski derivati - Google Patents

Substituirani 1,2,3,4-tetrahidronaftalenski derivati

Info

Publication number
SI1000048T1
SI1000048T1 SI9830343T SI9830343T SI1000048T1 SI 1000048 T1 SI1000048 T1 SI 1000048T1 SI 9830343 T SI9830343 T SI 9830343T SI 9830343 T SI9830343 T SI 9830343T SI 1000048 T1 SI1000048 T1 SI 1000048T1
Authority
SI
Slovenia
Prior art keywords
substituted
tetrahydronaphthalene derivatives
tetrahydronaphthalene
derivatives
Prior art date
Application number
SI9830343T
Other languages
English (en)
Inventor
Stefan Berg
Mats Linderberg
Svante Ross
Seth-Olov Thorberg
Bengt Ulff
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1000048T1 publication Critical patent/SI1000048T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9830343T 1997-07-25 1998-07-15 Substituirani 1,2,3,4-tetrahidronaftalenski derivati SI1000048T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702799A SE9702799D0 (sv) 1997-07-25 1997-07-25 New compounds
EP98934104A EP1000048B1 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
PCT/SE1998/001390 WO1999005134A1 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Publications (1)

Publication Number Publication Date
SI1000048T1 true SI1000048T1 (sl) 2003-04-30

Family

ID=20407828

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830343T SI1000048T1 (sl) 1997-07-25 1998-07-15 Substituirani 1,2,3,4-tetrahidronaftalenski derivati

Country Status (37)

Country Link
US (3) US6313118B1 (sl)
EP (1) EP1000048B1 (sl)
JP (1) JP3895923B2 (sl)
KR (1) KR20010022171A (sl)
CN (1) CN1270585A (sl)
AR (2) AR013370A1 (sl)
AT (1) ATE228510T1 (sl)
AU (1) AU739569B2 (sl)
BR (1) BR9811042A (sl)
CA (1) CA2296518A1 (sl)
DE (1) DE69809755T2 (sl)
DK (1) DK1000048T3 (sl)
DZ (1) DZ2569A1 (sl)
EE (1) EE04238B1 (sl)
ES (1) ES2187983T3 (sl)
HK (1) HK1025963A1 (sl)
HR (1) HRP980404B1 (sl)
HU (1) HUP0004334A3 (sl)
ID (1) ID24583A (sl)
IL (1) IL134108A0 (sl)
IS (1) IS5358A (sl)
MA (1) MA26521A1 (sl)
NO (1) NO315609B1 (sl)
NZ (1) NZ502384A (sl)
PL (1) PL338563A1 (sl)
PT (1) PT1000048E (sl)
RU (1) RU2194696C2 (sl)
SE (1) SE9702799D0 (sl)
SI (1) SI1000048T1 (sl)
SK (1) SK283918B6 (sl)
TN (1) TNSN98141A1 (sl)
TR (1) TR200000229T2 (sl)
TW (1) TW438781B (sl)
UA (1) UA69389C2 (sl)
WO (1) WO1999005134A1 (sl)
YU (1) YU2300A (sl)
ZA (1) ZA986588B (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0002729D0 (sv) * 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
SE0102856D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab A new method
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
CA2566934A1 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
WO2008130322A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 5-heterocyclyl-chromane derivatives for the treatment of pain
WO2008130319A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
WO2008130323A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 8-piperazine-tetrahydronaphtalene derivatives for the treatment of pain
WO2008130321A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
EP2098511A1 (en) 2008-03-07 2009-09-09 Solvias AG Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring
EA201001889A1 (ru) 2008-06-20 2011-08-30 Астразенека Аб Производные дибензотиазепина и их применение
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
AU2014282977B2 (en) 2013-06-21 2018-06-14 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919624A1 (de) 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) 1991-09-18 2002-04-25 Glaxo Group Ltd Benzanilidderivate als 5-HT1D-Antagonisten
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
CA2158457C (en) 1993-03-16 2001-04-17 Bertrand Leo Chenard Naphthalene derivatives
JPH09503773A (ja) 1993-10-19 1997-04-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１ｄレセプター拮抗剤用のベンズアニリド誘導体
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
AR013370A1 (es) 2000-12-27
AU739569B2 (en) 2001-10-18
CA2296518A1 (en) 1999-02-04
PL338563A1 (en) 2000-11-06
KR20010022171A (ko) 2001-03-15
HK1025963A1 (en) 2000-12-01
SE9702799D0 (sv) 1997-07-25
HRP980404A2 (en) 1999-04-30
IL134108A0 (en) 2001-04-30
YU2300A (sh) 2002-10-18
US20010051623A1 (en) 2001-12-13
US6534652B2 (en) 2003-03-18
IS5358A (is) 2000-01-24
NZ502384A (en) 2001-05-25
TW438781B (en) 2001-06-07
DZ2569A1 (fr) 2003-02-15
ID24583A (id) 2000-07-27
TR200000229T2 (tr) 2000-06-21
SK188399A3 (en) 2000-07-11
DK1000048T3 (da) 2003-03-03
ES2187983T3 (es) 2003-06-16
EP1000048B1 (en) 2002-11-27
JP2001510837A (ja) 2001-08-07
US6313118B1 (en) 2001-11-06
MA26521A1 (fr) 2004-12-20
BR9811042A (pt) 2000-08-15
AU8370398A (en) 1999-02-16
HUP0004334A3 (en) 2002-10-28
CN1270585A (zh) 2000-10-18
ATE228510T1 (de) 2002-12-15
EP1000048A1 (en) 2000-05-17
HUP0004334A2 (en) 2001-03-28
US20010051626A1 (en) 2001-12-13
PT1000048E (pt) 2003-03-31
SK283918B6 (sk) 2004-05-04
TNSN98141A1 (fr) 2005-03-15
ZA986588B (en) 1999-01-25
DE69809755D1 (de) 2003-01-09
RU2194696C2 (ru) 2002-12-20
EE04238B1 (et) 2004-02-16
AR046193A2 (es) 2005-11-30
JP3895923B2 (ja) 2007-03-22
NO315609B1 (no) 2003-09-29
WO1999005134A1 (en) 1999-02-04
DE69809755T2 (de) 2003-07-17
NO20000356D0 (no) 2000-01-24
UA69389C2 (uk) 2004-09-15
HRP980404B1 (en) 2002-10-31
EE200000041A (et) 2000-10-16
US6410532B2 (en) 2002-06-25
NO20000356L (no) 2000-03-27

Similar Documents

Publication Publication Date Title
HK1025963A1 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
HUP9903965A3 (en) Substituted 6,5-hetero-bicyclic derivatives
HK1019597A1 (en) Substituted 6, 6-hetero-bicyclic derivatives
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
PL337057A1 (en) 2-substituted 4,5-diarylimidazoles
PL334847A1 (en) Substituted 3-heterocyclyl-benzoyl derivatives
HRP980043B1 (en) 8-substituted-1,3,8-triazaspiro/4,5/ decan-4-on derivatives
IL126070A0 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
IL136500A0 (en) 1,4-diazacycloheptane derivatives
AU7449998A (en) 2,3-dihydrobenzofuran derivatives
AUPP003297A0 (en) 4,5-diaryloxazole compounds
HRP970162A2 (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
HU9800889D0 (en) New naphtylpiperazine derivatives
HUP9903001A3 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives
ZA965384B (en) 4-Amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds
SI1025094T1 (sl) Substituirani indanski derivati
GB9815537D0 (en) 2,6-Quinolines
PL317919A1 (en) Novel derivative of 3,4-pyrollodicarboxylimide
PL317918A1 (en) Novel derivative of 3,4-pyrollodicarboxylimide
PL317916A1 (en) Novel derivative of 3,4-pyrollodicarboxylimide
PL322697A1 (en) Novel compound - furane derivatives